View More View Less
  • 1 Debreceni Egyetem, Debrecen, Nagyerdei krt. 98., 4032
Open access

Absztrakt:

Jelenleg a COVID–19 kezelésére bizonyítottan hatékony terápia nem áll rendelkezésre. Az alábbiakban a teljesség igénye nélkül az ilyen vonatkozásban leginkább vizsgált gyógyszerek kerülnek bemutatásra. A felsorolt terápiás lehetőségek mindegyike kísérletinek tekintendő ebben a fázisban. Tekintettel a járvány súlyos népegészségügyi hatásaira, illetve az intenzív osztályon kezelt COVID–19-betegek potenciálisan fatális kimenetelére, ’off-label’ alkalmazásuk mégis megfontolandó. Orv Hetil. 2020; 161(17): 685–688.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). CDC, Atlanta, GA, 2020 March 21. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html.

  • 2

    Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9: e00221-18. .

    • Crossref
    • Export Citation
  • 3

    Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11: 222.

  • 4

    National Institutes of Health, National Library of Medicine. Adaptive COVID-19 Treatment Trial (ACTT). NIH, Bethesda, MD, 2020 March 27. Available from: https://clinicaltrials.gov/ct2/show/NCT04280705.

  • 5

    National Institutes of Health, National Library of Medicine. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734TM) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. NIH, Bethesda, MD, 2020 March 26. Available from: https://clinicaltrials.gov/ct2/show/NCT04292730.

  • 6

    National Institutes of Health, National Library of Medicine. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734TM) in participants with severe coronavirus disease (COVID-19). NIH, Bethesda, MD, 2020 March 26. Available from: https://clinicaltrials.gov/ct2/show/NCT04292899.

  • 7

    Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015; 212: 1904–1913.

  • 8

    Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252–256.

  • 9

    Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 Mar 18. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 10

    Surviving Sepsis Campaign. COVID-19 Guidelines. SSC, Mount Prospect, IL, 2020 March 20. Available from: https://sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19.

  • 11

    Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020 Mar 10. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 12

    Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020 Mar 4: 105932. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 13

    Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30: 269–271.

  • 14

    Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72–73.

  • 15

    Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 17. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 16

    Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.

  • 17

    Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 18

    Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 19

    Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Mar 13. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 20

    Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020 Mar 21. Available from: https://doi.org/10.1093/ofid/ofaa102.

  • 21

    Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395: 473–475.

  • 22

    Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Mar 11. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 23

    European Society of Cardiology. Position Statement of the ESC Council on hypertension on ACE-inhibitors and angi. ESC, Sophia Antipolis, 2020 March 13. Available from: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.html.

  • 24

    Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020 Mar 20. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 25

    Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368: m1086. Doi: https://doi.org/10.1136/bmj.m1086 (Published 17 March 2020).

  • 26

    European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. EMA, Amsterdam, 2020 March 18. Available from: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19.html.